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bstract
ackground: Traditional Tibetan medicine (TTM) plays an important role in the health care system of China. Little is known about the current
vidence of TTM’s clinical research in China.
ethods: Randomized controlled trials (RCTs) of TTM therapies conducted in China were searched in PubMed, Cochrane Library, two major
hinese electronic databases, and two Tibetan medical journals from their inception to June 2014. Qualitative analysis and reporting quality
ssessment were performed. The protocol was registered in PROSPERO (No: CRD42013006881).
esults: A total of 227 RCTs involving 29,179 participants were included. They were heterogeneous in terms of study size, sites, treated conditions,
nterventions, measured outcomes, and quality. 103 diseases or symptoms were reported in the included trials. TTM interventions used in the RCTs
onsisted of drug treatments and non-drug treatments including bloodletting and moxibustion, in which Tibetan patent medications for oral use
ere tested in 175 studies and for external use in 47 studies. 93.8% (213/227) of the trials reported superior effect of TTM over control interventions.
nly 7.9% (18/227) of the trials described details of random sequence generation, 3.5% (8/227) described details of blind.
onclusions: Clinical research in TTM in China covers whole medical systems. Data from RCTs showed that TTM might have potential benefit
or the management of many diseases. Studies on definitive health outcomes could be systematically reviewed in order to provide more information
n TTM’s efficacy. More efforts should be made to improve the quality of RCTs in China and support TTM’s further clinical applications.
2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
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Traditional Tibetan medicine (TTM), also called “Ggso ba
ig pa” in Tibetan, is a centuries-old traditional medical system
ased on the beliefs and practices of Tibetan culture. Originated
rom 2300 years ago, TTM absorbed plenty of medical theories
nd clinical techniques from early traditional Indian, Chinese,
nd Greco-Arab medicine in the 8th century, and has devel-
ped into a unique and mainstream medical system in Tibet
∗ Corresponding author. Tel.: +86 1064932939.
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icenses/by-nc-nd/4.0/).ince then [1,2]. Currently, TTM still plays an important role
n health care system of China, especially in Tibetan regions. In
ibet Autonomous Region (TAR) and other provinces of Tibetan
egions, the number of physicians practicing TTM was over
200 in 1993 [3], and rose to at least 5000 in 2010 according to
fficial statistics [4,5]. Additionally, many conventional western
edicine physicians in Tibetan regions often incorporate TTM
iagnostic and treatment into their clinical practices. In interior
hina, a majority of Tibetan patent medications are available in
harmacies and hospitals.
In TTM, the fundamental theory is “three elements” theory,
onsisting of “rLung”, “mKhris-pa”, and “Badkan”. Among
he three elements, rLung represents wind or air, govern-
ng the respiratory system, blood circulation, sensory organs,
nd movement; mKhris-pa represents fire, helping digestion,
ccess article under the CC BY-NC-ND license (http://creativecommons.org/
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ccelerating the decomposition of waste, absorbing heat energy
rom food, and producing heat energy. Badkan represents water
nd earth, providing nutrition for the body to maintain mois-
ure, and is responsible for digestive and metabolic systems
6]. It is necessary to maintain the balance of three elements
o as to keep normal functions of human body. A com-
lex approach such as pulse analysis, urinalysis, palpation,
nd inquiry is employed for diagnosing illnesses. Treatments
or restoring and maintaining balance between these elements
ainly include dietary and behavior modification, medicines
omposed of natural materials and external therapy (e.g. med-
cated baths, acupuncture, moxibustion, yoga, etc.). Based on
he general principle of holism and individualized treatment,
TM is believed to have potential benefits for the management
f many diseases, like circulatory and psychosomatic disor-
ers [7–9].
In recent decades, evidence-based medicine (EBM) has
ecome increasingly important for traditional medicine resulting
n clinical studies being conducted not only in China but in west-
rn countries, aiming to evaluate TTM’s effectiveness and safety.
n 2013, a systematic review including 40 TTM clinical studies
vailable in western countries was published [9], providing read-
rs with meaningful data on status of TTM’s clinical research
n the west. However, no Chinese or Tibetan publications were
ncluded in that review. In China, though TTM has been used
s an important complementary treatment for a long time, there
as been no systematic summary of clinical research on TTM.
herefore, this study systematically searched and reviewed the
TM randomized clinical trials (RCTs) conducted in China, in
rder to summarize the situation and identify common trends in
his field.
ethods
rotocol and registrations
The protocol of this systematic overview was regis-
ered in PROSPERO funded by the UK National Institute
or Health Research (CRD42013006881 Available from
ttp://www.crd.york.ac.uk/PROSPERO/display record.asp?ID
CRD42013006881). The protocol was presented in Supporting
nformation Captions 1 (S1).
ligibility criteria
All randomized clinical trials investigating the use of
TM in treating diseases and being conducted in China
ere eligible for inclusion. No restriction on language and
ublication type was applied. Trials were excluded if any
f the following are identified: (1) treatment group used
ome other medical treatments integrated with TTM interven-
ions (for example, a western medicine drug plus a Tibetan
atent medicine), and control group only used the same
TM interventions with treatment group. (2) Any dupli-
ate publications identified were removed and only assessed
nce.
Q
urative Medicine 7 (2015) 450–459 451
earch strategy
Electronic literature searches were carried out in PubMed,
ochrane Library (Issue 6, 2014), China National Knowledge
nfrastructure (CNKI) and Wanfang Database. The details of
earch strategy were as follows:
1) “Medicine, Tibetan Traditional” [Mesh] AND (random [All
Fields] was conducted in searching PubMed.
2) “Tibetan medicine” [Title, Abstract, Keywords] and “ran-
dom*” [Search All Text] were conducted in searching
“Trials” database of Cochrane Library.
3) (“zangyi” or “zangyao” or “zangxiyi jiehe”) [Theme] and
“suiji” [All Text] were applied in searching CNKI.
4) (“zangyi” or “zangyao” or “zangxiyi jiehe”) [Title, Key-
words] and “suiji” [All Text] were applied in searching
Wanfang Database.
(Note: “zangyi” means TTM; “zangyao” means traditional
ibetan pharmacy; “zangxiyi jiehe” means integration of TTM
nd western medicine; “suiji” means random*. All of them are
inyin of Chinese character.)
Tibetan literature was hand-searched in two Tibetan medical
ournals (in Tibetan language): China’s Tibetan Medicine and
raditional Tibetan Medical Education and Research, for any
ibetan literature that had not yet been included in electronic
atabases yet. Databases were searched from their inception up
ntil June 2014.
tudy selection
Three researchers independently identified and checked each
tudy against the inclusion criteria. H.L. and Q.W. selected
tudies from electronic databases. H.L. and Z.X.L.B. selected
tudies from two Tibetan medical journals (2007–2014). Firstly,
he titles and abstracts of the search results were screened, and
hen full papers for all possibly relevant trials were obtained.
econdly, irrelevant and duplicated papers were excluded.
astly, the remaining papers were re-checked by all researchers
ogether, and then the final studies were included for the review.
ata extraction
A structured data extraction form was designed (H.L. and
.J.Z.). Three authors (H.L., Q.W., and Z.X.L.B.) used the form
o extract the data independently. Any disagreements among the
uthors were discussed for consensus. The data extraction form
nvolved study information as followed: (1) citation; (2) study
esign: study sites, participants, interventions in treatment and
ontrol groups, course of treatment, outcomes; (3) study method-
logy elements: randomization method, allocation concealment,
linding, and outcome measures and summary of results.uality assessment
Methodological quality of included studies was evaluated
sing criteria from the Cochrane Handbook for Systematic
452 H. Luo et al. / European Journal of Integrative Medicine 7 (2015) 450–459
CNKI: n = 825 
Wanfang Data: 
n = 150 
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Cochrane Library: 
n = 17 
Records screened 
n = 1005 
Records excluded 
Duplicated records: n = 109 
Irrelevant papers: n = 630 
Full-text arcles assessed for 
eligibility 
n = 266 
Full-text arcles excluded due 
to non-randomized controlled 
trials, case series and trials 
conducted not in China  
n = 39
Studies included in
qualitave synthesis 
n = 227
Hand search in 
two Tibetan 
journals: n = 5 
Abbreviations: PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-
                          Analyses; CNKI: China National Knowledge Infrastructure;
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None were in the Tibetan language. All studies were conducted
in China.Fig. 1. PRISMA Flow chart: lite
eviews of Interventions [10]. Studies were appraised according
o the risk of bias for each item, including completeness of repor-
ing on generation of random allocation sequence, allocation
oncealment, blinding, and outcome. The quality of all included
tudies was categorized as low/unclear/high risk of bias. Trials
hat met all the criteria were categorized as low risk of bias,
hose that met none of the criteria were categorized as high risk
f bias, and the rest were categorized as unclear risk of bias if
nsufficient information was available to make a judgment.
ata analysis
Data analysis was presented by counts, percentage and fre-
uency. Microsoft Excel (version 2010) was applied for data
xtraction and analysis. RevMan software 5.2 was to be applied
o conduct meta-analysis if the trials had a good homogeneity of
tudy design, participants, interventions, control, and outcome
easures.
esults
tudy selection
Searches of the four databases and two journals identified
005 papers. The majority were ineligible on reading the titles
nd abstracts. After duplicates among databases and irrelevant
rticles were removed, the remaining 266 papers were identified
or full text review. Finally, 227 studies were included (Fig. 1).
F
msearching and study selection.
he references were presented in Supporting Information Cap-
ions 2 (S2).
Publication year of included studies ranged from 1989 to
014. The quantity of publications increased especially after
009. There were a larger number of studies in the past four years
between 2011 and 2014) compared with other years (n = 101
tudies, 44.5%) (Fig. 2). Of these included studies, one was pub-
ished in English [11], and the remaining 226 were in Chinese.ig. 2. Publication number of randomized clinical trials of traditional Tibetan
edicine conducted in China.
H. Luo et al. / European Journal of Integ
Table 1
Seven most productive study centers of TTM.
Center Name Medical system Number of
studies
Tibetan Medicine Hospital of Qinghai
Province
TTM 20
Beijing Tibetan Hospital of China
Tibetology Research Center
TTM 10
Tibetan Hospital of Tibetan
Autonomous Region
TTM 8
Medical College of Qinghai University Comprehensive 7
Hebei United University Affiliated
Hospital
WM 6
Gansu Provincial Hospital of
Traditional Chinese Medicine
TCM 4
People’s Hospital of Tibetan
Autonomous Region
WM 4
Abbreviation: TTM, traditional Tibetan medicine; TCM, traditional Chinese
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Drug Administration, 5.3% (4/76) were decoctions, and 1.3%edicine; WM, western medicine; Comprehensive: including TTM, TCM, and
M.
tudy characteristics
ample size
In total, 29,179 participants were involved in these 227 stud-
es. The sample size of the included studies ranged from 16 to
058 with an average of 128 participants per trial. Only two
tudies [11,12] reported the calculation method of sample size.
tudy sites
Among the included studies, 52 (22.9%) were carried out
n TTM hospitals, 37 (16.3%) in TCM hospitals, 122 (53.7%)
n western medicine hospitals (mainly refers to comprehensive
ospitals), 7 (3.1%) were multi-center RCTs, of which in 3 stud-
es all centers were in comprehensive hospitals, and in 4 studies
enters included more than two kinds of hospitals. 9 (4.0%)
tudies did not report any information on study sites. Seven
ost research intensive centers were presented in Table 1. A
eographic map was drawn to show the regional distribution of
tudy sites according to provinces in China (Fig. 3).
articipants and diseases
A total of 103 diseases or symptoms were reported in the
ncluded trials. Diagnostic criteria varied. The majority followed
onventional western medicine criteria, such as diabetes and
ypertension; while others recruited participants with certain
iseases, symptoms, or syndromes according to TTM or TCM,
uch as cough and insomnia. All the diseases could be summa-
ized into 15 categories according to International Classification
f Diseases-10 (ICD-10) (Fig. 4). The top 10 common diseases
alculated by study numbers were osteoarthritis (14 studies),
hronic hepatitis B (11 studies), chronic gastritis (9 studies),
bnormal menstruation (7 studies), eczema (7 studies), gout (7
tudies), stroke (7 studies), peptic ulcer (6 studies), hyperlipi-
emia (6 studies), and reaction to high altitude (6 studies).
In clinical practice of TTM and TCM, apart from diagno-
is of diseases by western medicine, sometimes the syndrome
(
4
frative Medicine 7 (2015) 450–459 453
ifferentiation (also called “pattern differentiation”) was added
o make clinical decisions. In this review, 19 studies used syn-
rome differentiation according to TTM, 33 used syndrome
ifferentiation according to TCM, and 175 did not use any
yndrome differentiation.
nterventions
Among the 227 studies, a majority of 213 (93.8%) reported
rials with 2 arms, and 14 reported 3 or more arms in one study.
he duration of the studies ranged widely from several days to
0 months. 22 studies did not report this item.
Interventions in the treatment group involved TTM interven-
ions alone (149 studies), TTM combined with TCM treatments
42 studies), and TTM combined with conventional western
edicine treatments (36 studies).
TTM interventions could be divided into two categories: drug
reatments for oral or external use (including Tibetan patent med-
cations, decoctions, medicated bath, retention enema, etc.) and
on-drug treatments (including bloodletting and moxibustion).
he majority of studies used oral Tibetan patent medications,
ccounting for 77.1% (175/227) of the studies. The second most
requently used treatments were Tibetan patent medications for
xternal use, accounting for 20.7% (47/227). The five most com-
on treatments investigated in the included trials were Xiaotong
aste (22 studies), Qingpeng ointment (20 studies), Nengxiao 6
apsule (14 studies), Duyiwei capsule (12 studies), and Gui-
iu 25 pill (8 studies). Xiaotong paste and Qingpeng ointment
ere produced by Tibet Cheezheng Tibetan Medicine Co., Ltd.
engxiao 6 capsule (also called zhigye drugpa in Tibetan) was
roduced by Tibet Tibetan Medicine Group Co., Ltd. Duyiwei
apsule was produced by Gansu Duyiwei Biological Pharma-
eutical Co., Ltd. Guijiu 25 pill (also called aolse nyer Lang
n Tibetan) was produced by several pharmaceutical compa-
ies including Cheezheng Tibetan Medicine and Crystal Beads
ibetan Medicine Group.
A whole medical system approach with complex TTM inter-
entions was used in 19 studies, in which patients in TTM
roups were given different Tibetan patent medicines or adjusted
ibetan patent medicines at different times within one day, and
djusted Tibetan patent medicines were performed by adding rel-
vant Tibetan medicinal powders to patent medicines according
o the patient’s TTM syndrome on an individual basis.
In control group, the interventions could be divided into four
ategories: TCM treatments (23.3%, 53 studies), conventional
estern medicine treatments (69.2%, 157 studies), placebo or
lank (The term ‘blank’ in this context means that none of inter-
entions is used for participant) control (2.6%, 6 studies), and
ther TTM treatments (10.1%, 23 studies). The combination of
nterventions from two categories was used in 4 studies’ control
roups. A majority (93.4%, 71/76) of TCM and TTM treat-
ents were patent medicines approved by China’s Food and1/76) was acupuncture. In placebo or blank control category,
studies used capsule placebo [13–16], 1 used ointment base
or placebo comparing with ointment [17]; 1 used blank control
454 H. Luo et al. / European Journal of Integrative Medicine 7 (2015) 450–459
l distribution of study centers in China.
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Table 2
Outcome measures reported in RCTs of TTM in China.
Outcome measure Number of studies Percent (n/227)
Effectiveness 187 82.4%
Clinical symptoms 92 40.5%
Laboratory tests 55 24.2%
Clinical tests 27 11.9%
Final outcome indexes 15 6.6%
Others 15 6.6%
Abbreviation: RCTs, randomized controlled trials; TTM, traditional Tibetan
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gFig. 3. Geographic map of regiona
omparing with rhodiola in preventing acute mountain sickness
18].
ffects and safety of TTM interventions
utcome measures
Assessed outcomes included effective rate, clinical symp-
oms (such as symptom score, or symptom relieving time),
aboratory tests, clinical tests (such as blood pressure, mus-
ular tension, or function score), final outcome indexes (such
s mortality rate, recurrence rate, or events rate), and others,
uch as quality of life, microbiology, histology, and iconogra-
hy. The most frequently reported outcome index was ‘effective
ate’. This was a composite index involving the improvement of
ymptoms, signs, laboratory tests, and others together, and usu-
lly the effectiveness of intervention was classified into three
r four grades: cured, (marked effective), effective, ineffective.
his outcome measurement has been widely used in TTM and
CM clinical research in China for decades mainly due to the
uidelines for clinical research on Chinese new herbal medicines
19]. Among the included 227 studies, 187 (82.4%) used for
ffectiveness assessment; however, the majority did not report
dequate information for each outcome, and great inconsistency
as found on the methods for grading effective rate among these
tudies (Table 2).ffects
Some diseases were researched in several trials. For
xample, chronic hepatitis B was treated with complex TTM
i
g
[
iedicine.
nterventions in 2 studies [20,21]: In Gazang’s study [21], 220
ases of hepatitis B patients were randomly divided into inte-
rative group and western medicine group. Interventions in the
ntegrative group consisted of TTM and western medicine treat-
ents. TTM treatments contained Songshi (turquoise) 25 pill in
he morning, Honghua (safflower) 13 pill in the noon, and Shiliu
pomegranate) Jianwei pill at night. Interventions of western
edicine were the same antiviral therapy in both groups. After
period of three to six months, results showed that effective rates
ere 88.1% in integrative group and 46.4% in western medicine
roup (P < 0.05).
Some Tibetan patent medicines’ effectiveness was investi-
ated in treating different diseases. For example, Songshi 25 pill
n 4 studies [22–25], and Lvronghao 25 pill [26], Gandanqing 7
ranules [27], Zangyinchen capsule [28], or Gantaishu capsule
29] in each study respectively. Xiaotong paste was investigated
n treating pain such as acute stomach pain [30], soft tissue
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njuries [31], heel pain [32], low back pain [33], osteoarthritis
34], and so on.
The majority of studies (213, 93.8%) reported positive results,
uggesting that the effectiveness of TTM (or TTM combined
ith control interventions) was superior to control interventions,
nd then recommending generalizing their TTM treatments to a
roader clinical application. 12 studies reported neutral results,
uggesting the effectiveness of TTM treatment was equivalent
o that in the control group. Only 2 studies reported negative
esults: Zhang’ s study [35] compared the effectiveness between
reatment group (integration of a Tibetan drugs Sanpu Xinnao
t
i10) in randomized clinical trials of traditional Tibetan medicine in China.
in capsule and fluoxetine) and control group (fluoxetine alone)
n treating senile depression, showing that there was no sig-
ificant difference between the two groups; Shen’s study [36]
ompared the effects of diclofenac diethylamine emulgel with
Tibetan external medication Qingpeng ointment on shoulder
eriarthritis, showing that diclofenac diethylamine emulgel was
ore effective in improving the function of shoulder joint than
TM treatment.Meta-analysis could not be employed due to the inconsis-
ency and heterogeneity of study design, participants, diseases,
nterventions, controls, and outcome measures.
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afety
A total of 104 (45.8%) studies reported this outcome, of
hich 22 studies stated that no adverse events occurred in both
roups, and the remaining 83 studies reported mild adverse
vents. For instance, nausea occurred in patients with peptic
lcer who took antibiotic and four Tibetan medicines (Renqing
hangjue, Zhituo jiebai pill, Hanshuishi 21 pill,Muxiang 13 pill)
t different time within one day [37]. Mild headache occurred
n patients with peptic ulcer who took three Tibetan medicines
Zuozhudaxi, Mubu Yujie, Yuqiong) [38], mild stomach discom-
ort occurred in patient with lumbar disc herniation who took
uyiwei capsule [39], mild stomach pain occurred in female
ith inflammation of the reproductive system who took Guijiu
5 pill [40], and skin allergy caused by Xiaotong paste for topi-
al analgesics [41–43]. No serious adverse effects were reported
n any studies.
ethodological quality
According to pre-defined methodological quality criteria,
nly three studies [11,17,45] were low of bias, and the majority
ad high or unclear risk of bias due to the incompleteness of
eporting on key methodological items. All the studies reported
hat participants were randomly divided into treatment group
nd control group, but only 7.9% (18 studies) described details
n random sequence generation. Among all the studies, 4 studies
11,17,44,45] reported concealment of allocation sequence, by
sing sealed opaque envelope or central randomization system.
.0% (16/227) of studies reported that blinding was used, of
hich 8 studies [11,13,15,17,44–47] provided sufficient infor-
ation on how blinding performed and who were the objects of
linding. Dropouts during the clinical research were reported in
0 trials, of which 3 [11,17,44] used intention-to-treat analysis.
verall, the methodological quality of included trials was not
romising (Fig. 5).
iscussionain ﬁndings of this overview
A systematic overview of RCTs on TTM which were con-
ucted in China was presented in this paper. A total of 227
g
T
J
dias graph.
CTs were included in this review, showing the great het-
rogeneous nature of the study design, sample size, diseases,
reatments, outcome measurements, and methodological qual-
ty. This phenomenon was similar to Reuter KP’s review [9]
n TTM clinical research available in the west, in which 40
tudies including RCTs, nonrandomized controlled trials, and
bservational studies, involving 4684 patients were included.
n his paper, all studies followed western medical diagnoses
nd 11 followed TTM diagnostics (syndrome differentiation),
overing a wide range of diseases including respiratory, circu-
atory, digestive, immune, orthopedic, pediatric diseases, and
epatitis. Herbal medicines were the main treatments in TTM
roup; assessed outcomes included clinical outcomes such as
ymptom scales, laboratory tests, clinical tests, and other; het-
rogeneity was found in quality assessment. Meanwhile, in
erms of total number of trials and study scope, TTM appli-
ation and research in China seemed to be wider than those in
he west.
The lists of top 10 common investigated diseases represented
tendency that TTM probably have potential advantages of
reating pain, liver diseases, digestive diseases, endocrine dis-
ases, and circulatory diseases. The integration of TTM and
CM or conventional western medicine also might be beneficial
o the improvement of clinical effectiveness under some condi-
ions. However, evidence from existing trials was weakened by
ethodological and reporting quality limitations. The conclu-
ion and recommendation drew from the majority of included
tudies should be interpreted with caution.
umber of RCTs on TTM
According to our search, the first RCT on TTM was pub-
ished in 1989 [14], later than that in the west. The number
f publications increased by years especially after 2004 due
o paralleled the popularization of evidence-based medicine
n China [48], and probably the establishment of policy on
eveloping and testing TTM. Publication numbers fell in 2013,
ossibly due to the decrement of RCTs testing single Tibetan
atent medicines, and most of which were products of a sin-
le company (Tibet Cheezheng Tibetan Medicine Co., Ltd).
he data in 2014 were incomplete since the search ended in
une 2014 and there was a time lag of literature inclusion by
atabases.
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ublication language of RCTs on TTM
The majority (99.6%, 226/227) of studies were written and
ublished in Chinese language, only one in English language
11], and none was in Tibetan. During the hand literature search
f two Tibetan medical journals (from 2007 to 2014), only one
bservational study was identified [49], no RCTs or other clin-
cal studies was published in these journals. Two factors might
ontribute to this interesting phenomenon. One was the com-
osition of the authors: the majority of authors of the included
rials from TCM or conventional western medicine hospitals
ere located in interior China, were not native Tibetan speakers
the regional distribution of study sites according to provinces
s presented in Fig. 3). Hence they could not write their papers
n Tibetan. The other was native Tibetan-speaker authors’ pref-
rence for writing and submitting papers. From our search and
creening of Tibetan journals and from discussions with native
ibetan-speaker TTM physicians, suggested that they preferred
o publish their traditional theoretical study and clinical experi-
nce in Tibetan language, in order to share their opinions with
TM colleagues, and publish clinical research in Chinese lan-
uage so as to make the effectiveness of TTM recognized by
ore readers.
iagnosis and syndrome differentiation of diseases
A total of 103 diseases or symptoms categorized to 15
ategories according to ICD-10 were investigated among the
CTs, suggesting the clinical research of TTM covered the
hole medical system. The majority followed diagnosis criteria
f western medicine, which could be attributed to the widely
sed practice of integrative medicine in China since 1950s
hen Chairman Mao Zedong made his famous speech on tra-
itional Chinese medicine (TCM), saying that “TCM should
ntegrate with western medicine organically.” Therefore, west-
rn diagnostic procedures and treatment had been integrated
ithin the practice of traditional medicines (including TCM,
TM, and other traditional medical systems) in China since
hen [50].
In this review, 16.3% (37/227) of included trials were
onducted in TCM hospitals, 53.7% (122/227) in western
edicine hospitals, while only 22.9% (52/227) in TTM hospi-
als, suggesting that some TTM therapies might be available in
on-TTM hospitals. After in-depth analysis, differences on syn-
rome differentiation among TTM and TCM/western medicine
esearchers were found as follows:
In trials conducted by TTM physicians, different kinds of
TM interventions were evaluated, including drug treatments
or oral or external use (such as Tibetan patent medica-
ions, decoctions, medicated bath, retention enema, etc.) and
on-drug treatments (including bloodletting and moxibus-
ion). A whole medical system approach with complex TTM
nterventions based on TTM syndrome differentiation was
pplied in 19 studies, all of which were conducted by TTM
hysicians, accounting for 36.5% (19/52) of all studies con-
ucted in TTM hospitals. Syndrome differentiation was not
mployed in the other 37 studies due to their objectives,
r
g
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hich was to evaluate the efficacy of certain Tibetan patent
edicines, other than the effectiveness of whole TTM system
pproach.
While for those studies conducted by TCM or conven-
ional western medicine researchers, all the TTM interventions
ere just single Tibetan patent medicines, of which the
ajorities were obtained from single pharmaceutical com-
anies in China (like Tibet Cheezheng Tibetan Medicine,
ibet Tibetan Medicine Group). A basic feature of TTM
nd TCM is the use of syndrome differentiation of diseases
sed to guide and determine of the clinical decision. Another
nteresting finding of this review was that 33 studies used
CM syndrome differentiation rather than TTM to deter-
ine TTM interventions. In other words, TCM physicians
sed Tibetan patent medications as Chinese patent medica-
ions based on their own conventional beliefs and practices of
CM.
ethodological quality of included trials
It also important to point out that the methodological qual-
ty of included studies were generally not promising (only
.9% of them described details of random sequence genera-
ion). As Wu T’ survey reported [51], most reports of RCTs
n TCM or western medicine published in some Chinese
ournals lack an adequate description of randomization. This
eemed to be a general phenomenon in China, as researchers
usually refers to clinicians) lacking sufficient training in clin-
cal research methodology and reporting guidelines of clinical
esearch papers, and many journals did not ask authors to provide
ethodological details. Therefore, although positive results
ere reported in 93.8% of the included trials in the overview,
ommonly the conclusions and recommendations were: “this
herapy is effective and safe, we suggest its generalization in
linical practice”, any firm conclusions of recommending cer-
ain TTM treatments for corresponding diseases could not be
rawn.
The designs of many studies were also problematic, espe-
ially for the applying control interventions and outcome
easures. Only 6 studies used placebo controls. 76 studies used
CM treatments (53) or other TTM treatments (23) as con-
rols, of which 71 used patent medicines approved by China’s
ood and Drug Administration. However, since there was a lack
f effective TTM or TCM treatments which were proved by
igouress randomized double-blind clinical trials, it was dif-
culty to test TTM’s effectiveness if such interventions were
aken for control. Besides, in some studies, interventions in treat-
ent group were TTM therapy combined with TCM decoctions,
hile the control group was conventional western medicine
reatments. In this case, it was hard to differentiate the specific
fficacy of TTM.
82.4% of the studies applied composite outcome index
effective rate) for effectiveness evaluation. However, the clas-
ification of “cured”, “effective”, “ineffective” within “effective
ate” were not internationally accepted for its’ clinical hetero-
eneity among studies, and it could not reveal the specific and
etailed effectiveness of TTM, either.
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imitations of this review
This review has its limitations. Firstly, despite the broad
iterature search, some studies in Tibetan language may not
ave been identified, for TTM papers could also be published
n several journals of Tibetan studies (in Tibetan language) in
hina, as well as some informal publications for internal com-
unication. Secondly, nearly all the included studies reported
ositive effects favoring TTM, with only 0.9% (2/227) hav-
ng negative reports might be a reflection of publication bias
n the studies covered by this review. Lastly, TTM’s RCTs
onducted in China were simply consolidated by descriptive
tatistics, lacking of in-depth analyses. This overview could
rovide readers with common trends of China’s TTM clinical
esearch, but failed to provide detailed information of TTM’
ffect for a certain health condition or provide definitive data on
fficacy.
uggestions for further study
For further study, there could be two approaches. Selecting
health outcome of interest and employing a systematic review
n the literature within this topic, might be more meaningful
o evaluate the efficacy of TTM. Conversely, the importance
f using CONSORT statement [52] in conducting and repor-
ing of RCTs on TTM should be emphasized, so as to improve
he quality of studies. In order to test TTM’s specific effective-
ess, rational interventions should be used in the treatment and
ontrol groups, against a standard positive therapy or placebo
ontrol. If non-TTM interventions (e.g. TCM, or conventional
reatments) are combined in treatment groups, they should be
sed as stand alone treatments in the control group. For effec-
iveness evaluation, standard outcome measures for specific
iseases are highly recommended for assessment of TTM’s
ffectiveness, and composite index should not be addressed as
primary outcome measure. Researchers should also pay more
ttention to monitoring and reporting the safety of TTM treat-
ent, especially for long-term studies. Journal editors should
sk authors to report full methodological details according to
elevant reporting guidelines prior to a manuscript’s accep-
ance. Researchers should be formally trained in clinical trial
ethodology.
onclusions
The results of this systematic review suggested that clin-
cal research of TTM was propagated rapidly in China, but
t is still at a nascent stage. Preliminary evidence from ran-
omized studies have shown that TTM might have potential
enefits for the management of many diseases. Studies on a
efinitive health outcome could be systematically reviewed so
s to provide more information on TTM’s efficacy. More efforts
hould be made by researchers and editors to improve the
uality of RCTs in China and support TTM’s further clinical
pplication.
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